Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.

Interstitial lung disease (ILD) causes significant morbidity and mortality in patients with systemic autoimmune rheumatic diseases. Patients at high risk of ILD should be screened using ...

Please provide your email address to receive an email when new articles are posted on . Use of race-specific lung function equations resulted in misclassification of patients with ILD eligible for ...

The Program for Pulmonary Fibrosis and Interstitial Lung Disease's mission is to provide state of the art evaluation and treatment for patients with interstitial lung diseases (ILD). The University of ...

Please provide your email address to receive an email when new articles are posted on . Patients receiving nintedanib demonstrated slowed function deterioration compared with those receiving placebo.

EULAR—The European Alliance of Associations for Rheumatology—has worked with the European Respiratory Society (ERS) to develop new clinical practice guidelines for interstitial lung disease (ILD) ...

We demonstrated that vitamin D deficiency and insufficiency are highly prevalent in a cohort of patients with ILD and are associated with the presence of an underlying CTD independent of other ...